Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
PMID: 28097194
This cautious approach can be attributed to the historical context of Rimonabant, a previously promising anti-obesity agent withdrawn from the market in 2008 due to severe psychiatric side effects 26
have been linked to dosing errors and adverse events
Garg and team
Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
US$ 24.11
US$ 25.62
US$ 26.34
